Locally Produced Tumor Necrosis Factor-α Mediates Interleukin-2-Induced Lung Injury

Circulation Research

Volumn 78, Issue 2, 1996, Pages 329-336

  Rabinovici, R ^a   Feuerstein, G ^b   Abdullah, F ^a   Whiteford, M ^a   Borboroglu, P ^a   Sheikh, E ^a   Phillip, D R ^a   Ovadia, P ^a   Bobroski, L ^a   Bagasra, O ^a   Neville, L F ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adult respiratory distress syndrome; Cytokines; Immunotherapy

Indexed keywords

CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG INJURY; LUNG TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRICETINAE; DOGS; HUMANS; INTERLEUKIN-2; LUNG; MALE; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030061423     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.78.2.329     Document Type: Article

References (53)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen JE, Motory YL, Skibber JM, Shiloni E, Vetto TJ, Scipp CA, Simpson C, Richer CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492.
2. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988;108: 853-858.
3. Rosenberg SA, Yang JC, Topalian SL, Schwartzentrubber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose IL-2. JAMA. 1994;271:907-913.
4. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137:1735-1742.
5. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J Immunol. 1987;139:1883-1888.
6. Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA. Toxicity of human recombinant interleukin-2 in the mouse is mediated by activated lymphocytes: separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest. 1988;59:598-612.
7. Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelium cells and cause their lysis. J Immunol. 1987; 138:1779-1785.
8. Numeroff RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. 1988;141:4250-4257.
9. Welbourn R, Goldman G, Kobitz L, Valeri CR, Shepro D, Hechtman HB. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg. 1990; 212:728-733.
10. Rabinovici R, Sofronski MD, Renz JF, Hillegas LM, Esser KM, Vernick J, Feuerstein G. Platelet activating factor mediates interleukin-2 induced lung injury in the rat. J Clin Invest. 1992;89: 1669-1673.
11. Rabinovici R, Sofronski MD, Borboroglu P, Spirig AM, Hillegas LM, Levine J, Vernick J, Scesney SM, Feuerstein N, Feuerstein G. Interleukin-2-induced lung injury: the role of complement. Circ Res. 1994;74:329-335.
12. Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ, Van der Vall H, Wagstaff J. Activation of the complement system during immunotherapy with recombinant IL-2. J Immunol. 1990;144:2419-2424.
13. Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema: comparison to septic acute lung injury. Am Rev Respir Dis. 1988;137: 1364-1370.
14. Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by tumor necrosis factor-α. Circ Res. 1990;67:68-77.
15. Owen-Schaub LB, de Mars M, Murphy EC Jr, Grimm EA. IL-2 dose regulates TNF alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol. 1991;132:193-200.
16. Heslop HE, Gottlieb DJ, Bianchi ACM, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. In-vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989;74:1374-1380.
17. Klausner JM, Morel N, Paterson IS, Kobitz L, Valeri CR, Eberlein TJ, Shepro D, Hechtman HB. The rapid induction by interleukin-2 of pulmonary microvascular permeability. Ann Surg. 1989;209: 119-128.
18. Stolpen A, Guinan E, Fiers W, Pober J. Recombinant tumor necrosis factor and immune interferon act singly and in combination to recognize human vascular endothelial cell monolayers. Am J Pathol. 1986;123:16-24.
19. Rabinovici R, Bugelski PJ, Esser KM, Hillegass LM, Vernick J, Feuerstein GZ. ARDS-like lung injury produced by endotoxin in platelet activating factor primed rats. J Appl Physiol. 1993;74: 1791-1802.
20. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MR. Activation of human polymorphonuclear neutrophil functions by interferon gamma and TNFα. J Immunol. 1985; 135:2069-2073.
21. Jutila MA, Rott L, Berg EL, Butcher EC. Function and regulation of the neutrophil MEL-14 antigen in-vivo: comparison with LFA-1 and Mac-1. J Immunol. 1989;143:3318-3324.
22. Gamble JR, Harlan JM, Klebanoff SJ, Lopez AF, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985;82:8667-8671.
23. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427-451.
24. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol. 1993;15:409-413.
25. Turner CR, Esser KM, Wheeldon EB. Therapeutic intervention in a rat model of ARDS, IV: phosphodiesterase IV inhibition. Circ Shock. 1993;39:237-245.
26. Mulligan MS, Jones ML, Bolanowski MA, Baganoff MP, Deppeler CL, Meuers DM, Ryan US, Ward P. Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol. 1993;150:5585-5595.
27. Ulich TR, Howard SC, Remick DG, Wittwer A, Yi ES, Yin S, Guo K, Welply JK, Williams JH. Intra-tracheal administration of endotoxin and cytokines, VI: antibodies to CINC inhibit acute inflammation. Am J Physiol. 1995;268:L245-L250.
28. Zagorski J, DeLorco JE, Rat CINC (cytokine-induced neutrophil chemoattractant) is the homologue of the human GRO proteins but is encoded by a single gene. Biochem Biophys Res Commun. 1993;190:104-110.
29. Huang S, Paulauskis JD, Godleski JJ, Kobzik L. Rat CINC/KC cDNA and mRNA expression in lung macrophages and fibroblasts. Biochem Biophys Res Commun. 1992;184:922-929.
30. Rabinovici R, Rudolph AS, Vernick J, Feuerstein GZ. A new salutary resuscitative fluid: liposome encapsulated hemoglobin/ hypertonic saline solution. J Trauma. 1993;35:121-127.
31. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
32. Palleroni AV, Varesio L, Wright RB, Brunda MJ. Tumoricidal alveolar macrophage and tumor infiltrating macrophage cell lines. Int J Cancer. 1991;49:296-302.
33. 2 and cyclic nucleotides. J Immunol. 1988;141:2388-2394.
34. Hancock WW, Muller WA, Cotran RS. Interleukin-2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes and monocyte cell lines. J Immunol. 1987;138:185-192.
35. Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L. Interleukin-2 and human monocyte activation. J Leukoc Biol. 1995;57:13-21.
36. Lamy M, Thijs LG, eds. Mediators of Sepsis, Volume 16: Update in Intensive Care and Emergency Medicine. New York, NY: Springer-Verlag; 1992.
37. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg? Circ Shock. 1992;38:145-152.
38. Gemlo BT, Palladino MA Jr, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant IL-2 and LAK cells. Cancer Res. 1988;48:5864-5867.
39. Dubinnett SM, Huang M, Lichtenstein A, McBride WH, Wang J, Markovitz G, Kelley D, Grody WW, Mintz LE, Dhanani S. Tumor necrosis factor-alpha plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation. Cell Immunol. 1993;157:170-180.
40. Butler LD, Mohler KM, Layman NK, Cain RL, Ridel PE, Puckett LD, Bendele AM. IL-2-induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol Immunotoxicol. 1989;11:445-487.
41. Wei S, Blanchard DK, Liu JH, Djeu JY. Activation of tumor necrosis factor α production from human neutrophils by IL-2 via IL-2 receptor beta. J Immunol. 1993;150:1979-1987.
42. Strieter RM, Remick DG, Lynch JP, Spengler RN, Kunkel SL. Interleukin-2-induced TNFα gene expression in human alveolar macrophages and blood monocytes. Am Rev Respir Dis. 1989;139: 335-342.
43. Aramburu J, Balboa MA, Rodriguez A, Melero I, Alonso M, Alonso JL, Lopez-Botet M. Stimulation of IL-2-activated natural killer cells through the Kp-43 surface antigen up-regulates TNFα production involving the LFA-1 integrin. J Immunol. 1993;151: 3420-3429.
44. Edwards MJ, Abney DL, Heniford T, Miller FN. Passive immunization against TNFα inhibits IL-2-induced microvascular alternations and reduces toxicity. Surgery. 1992;112:480-486.
45. Fraker DL, Langstein HN, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med. 1989;170:1015-1020.
46. Quinn TD, Miller FN, Wilson MA, Garrison RN, Anderson JA, Lenz LG, Edwards MJ. Interleukin-2-induced lymphocyte infiltration of multiple organs is differentially suppressed by soluble tumor necrosis factor receptor. J Surg Res. 1994;56:117-122.
47. Edidin M, Aszalos A, Damjanovich S, Waldmann TA. Lateral diffusion measurements give evidence for association of the Tac peptide of the IL-2 receptor with the T27 peptide in the plasma membrane of HUT-102-B2 T cells. J Immunol. 1988;141:1206-1210.
48. Pober JS, Slowik MR, DeLuca LG, Ritchie AJ. Elevated cAMP inhibits endothelial cell synthesis and expression of TNFα-induced ELAM-1 and VCAM-1 but not ICAM-1. J Immunol. 1993;150; 5114-5123.
49. Ghersa P, Van Huijsduijnen RH, Whealan J, Cambet Y, Pescini R, DeLamarter JF. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. J Biol Chem. 1994;269: 29129-29137.
50. Sherry B, Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine and autocrine control of inflammatory responses. J Cell Biol. 1988;107:1269-1277.
51. Rabinovici R, Bugelski PJ, Esser KM, Hillegass LM, Griswold DE, Vernick J, Feuerstein GZ. Tumor necrosis factor-α mediates endotoxin-induced lung injury in platelet activating factor-primed rats. J Pharmacol Exp Ther. 1993;267:1550-1557.
52. Braquet P, Touqui L, Shen T, Vargaftig BB. Perspectives in platelet activating factor. Pharmacol Rev. 1987;39:97-145.
53. Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells: a potential mechanism for endothelial injury. J Immunol. 1988;141:158-163.